SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China. (See Beigene story this issue.) Read More
LUCKNOW, India – An Indian government-funded drug research institute plans to set up a biopharma industry incubation center to attract entrepreneurs in northern and central India, areas that are home to a number of high-quality research laboratories but are in dire need of bioclusters. Read More
TAIPEI, Taiwan – Pharmaengine Inc. said it submitted a new drug application (NDA) to the TFDA, Taiwan's drug regulatory body, for the liposome version of irinotecan, PEP02, as a second-line treatment for pancreatic cancer patients who have failed gemcitabine therapy. Read More
SHANGHAI – The Beijing-based oncology company Beigene Co. Ltd. continuing its string of upbeat news, announcing the first human dosing of its programmed death-1 (PD-1) antibody, BGB-A317, in Australia. Read More
Hanmi Pharmaceutical Co. Ltd., of Seoul, Korea, presented interim results of the phase I/II domestic trial of HM61713, an orally active epidermal growth factor receptor (EGFR) mutant selective inhibitor, in T790M mutation-positive non-small-cell lung cancer patients. Daily single administration of HM61713 800 mg showed 95.2 percent disease control rate (DCR) in 59 of 62 patients with T790M-positive mutation who developed resistance to previous EGFR tyrosine kinase inhibition. Read More
